With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age
as therapeutics, generating a market value of 11billionin2004,expectedtoreach 26 billion by …

The discovery of hybridoma technology, described by Kohler and Milstein in 1975, and the
resulting ability to generate monoclonal antibodies (mAbs) initiated a new era in antibody …

Nanobodies, single-domain antigen-binding fragments of camelid-specific heavy-chain only
antibodies offer special advantages in therapy over classic antibody fragments because of …

Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …

Nanobodies are the smallest fragments of naturally occurring heavy-chain antibodies that
have evolved to be fully functional in the absence of a light chain. As such, the cloning and …

In this review, we explain why and how rabbit monoclonal antibodies have become
outstanding reagents for laboratory research and increasingly for diagnostic and therapeutic …

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a
chronic and manageable disease. However, treatment is only effective until HIV-1 develops …

Intracellular antibodies (intrabodies) are recombinant antibody fragments that bind to target
proteins expressed inside of the same living cell producing the antibodies. The molecules …

Prevention of abnormal misfolding and aggregation of α synuclein (syn) protein in
vulnerable neurons should be viable therapeutic strategies for reducing pathogenesis in …

In biomedical research there is an ongoing demand for new technologies, which help to
elucidate disease mechanisms and provide the basis to develop novel therapeutics. In this …